- Home
- CD vs LAB Comparison
CD vs LAB Comparison
Compare CD & LAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CD | LAB |
|---|---|---|
| Founded | 2011 | 1999 |
| Country | United States | United States |
| Employees | 11 | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Laboratory Analytical Instruments |
| Sector | Technology | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 448.6M | 488.4M |
| IPO Year | N/A | 2011 |
Fundamental Metrics
Financial Performance| Metric | CD | LAB |
|---|---|---|
| Price | $6.11 | $1.54 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $1.35 |
| AVG Volume (30 Days) | 156.5K | ★ 1.6M |
| Earning Date | 08-31-2023 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $956,830.00 | ★ $169,737,000.00 |
| Revenue This Year | $949,544.10 | N/A |
| Revenue Next Year | $14.69 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 33.48 | ★ 79.77 |
| 52 Week Low | $1.38 | $0.92 |
| 52 Week High | $36.77 | $1.89 |
Technical Indicators
Market Signals| Indicator | CD | LAB |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 53.56 |
| Support Level | N/A | $1.50 |
| Resistance Level | N/A | $1.67 |
| Average True Range (ATR) | 0.00 | 0.10 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 0.00 | 70.13 |
Price Performance
Historical ComparisonAbout CD Chaince Digital Holdings Inc. Ordinary Shares
Chaince Digital Holdings Inc is digital fintech company providing access to the growing AI-powered infrastructure, blockchain, and digital assets. Its three core business lines include: blockchain and digital asset solutions, AI and HPC infrastructure, developing liquid cooling solutions for AI data centers and comprehensive financial services through Chaince Securities,LLC a FINRA-registered broker-dealer, and RIA.
About LAB Standard BioTools Inc.
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. Its segments include Proteomics and Genomics. It generates maximum revenue from the Proteomics segment. Geographically, it derives a majority of its revenue from the Americas.